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OBJECTIVE: Evaluate earnings associated with early,
late, or any stages of ARM, a progressive vision-compro-
mising condition, compared to a general elderly cohort.
METHODS: Earnings of an ARM population 65 years
and a general cohort 65 years were retrospectively eval-
uated to estimate potential earnings differences. ARM
prevalence data were obtained from prospective land-
mark studies in the US, Australia, and The Netherlands.
Prevalence data and census data, were used to estimate
the number of ARM patients in these countries. Beaver
Dam (BD) study income data were used to calculate the
median income for each stage of ARM. US Social Secu-
rity (SS) median income data for the general cohort pop-
ulation 65 was calculated using identical BD income
categories. BD income was adjusted for inflation and re-
gional differences. By multiplying the estimated number
of patients per given country within each specified earn-
ings category of ARM by respective median incomes, an-
nual societal earnings were calculated. Likewise, multi-
plying the number of elderly without ARM by the SS
median annual income produced an income estimate of
persons without ARM. RESULTS: Estimated BD in-
comes for persons with ARM 65 years were $27,000,
$21,000 and $27,000 for the early, late, and any groups,
respectively. The income for the general population 65
was estimated at $31,000. The early ARM group has
higher earnings related to the higher prevalence of this
cohort, and possibly higher per capita income in what is
likely to be a younger sub-population. Total estimated
earnings for the any ARM group were $240 billion. By
comparison, the total income for “no” ARM was $803
billion. ARM patients are 26% of the 65 years popula-
tion but earn only 23% of this group’s income. This pat-
tern was repeated across five studies. CONCLUSION:
The wage impact associated with ARM appears large and
represents a significant indirect societal cost of AMD.
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OBJECTIVE: To define actual practice patterns for glau-
coma and estimate the resources utilization, total cost of
treatment and costs distribution in patients categorised
into groups according to type of glaucoma and then
stratified according to stage of illness. METHODS: The
observational study included 193 patients with open-angle
(OAG) and 122 patients with closed-angle glaucoma
(CAG) recruited by ophthalmologist in Mazowian Re-
gional Centre of Glaucoma Diagnosis and Treatment. Pa-
tients were categorised into OAG and CAG groups and
then stratified according to intraocular pressure (16
mmHg-I, 17–22 mmHg-II, 22 mmHg-III) or changes in
C/D (C/D0,5-a, C/D0,6-b). Number of eyes in exam-
ined subgroups were: OAG I-154, II-165, III-45, 1–124,
2–240; CAG I-113, II-74, III-40, 1–114, 2–113, respec-
tively. The perspective of health-care payers and time ho-
rizon 18 months were taken. Quantities of resources or
services used and their costs were collected separately,
and then quantities multiplied by the price. Costs were
summarized for the main resource categories (pharma-
ceuticals, outpatient consultations, surgery, laser ther-
apy). Resources used and costs in each group were calcu-
lated per 100eyes/1year, what permitted a cross-group
comparison. RESULTS: The total cost of glaucoma treat-
ment was highest in CAG-III (108032 PLN/100eyes/1year,
1 USD  4,5 PLN) and OAG-III or b (99400 PLN/
100eyes/1year). The major cost driver in CAG-a and
OAG-b was surgery (36% of total costs), in all other,
mostly in stage III, were pharmaceuticals: in OAG-III and
CAG-III–50%, in OAG-b – 40% of total costs. In OAG-2
and CAG-b, CAG-I and CAG-II 30% of total costs arose
from surgery. The most frequent used pharmaceuticals
were: in OAG–timolol, in CAG–pilocarpine. The third–
dorzolamid-was used in OAG nad CAG, most frequent
in stage III. CONCLUSION: The total cost of glaucoma
treatment and costs distribution depends on the severity
of illness. Beyond CAG-a and OAG-b group, the most
expensive was pharmacological treatment.
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OBJECTIVE: To compare costs and effects of continuous
terbinafine and intermittent itraconazole in the treatment of
toenail onychomycosis in Poland. This was intended to
facilitate the decision-making process in selecting the more
cost-effective treatment for toenail onychomycosis. METH-
ODS: L.I.O.N. study results were used to estimate effec-
tiveness of terbinafine 0,25 g/d for 12 or 16 weeks (T12,
T16) and itraconazole 0,4 g/d for 1 week in every 4 weeks
for 12 or 16 weeks (I3, I4). The measure of treatment ef-
fectiveness was complete cure and average number of dis-
ease-free days per patient. Direct medical costs were esti-
mated on the basis of current treatment patterns in Poland.
The perspective of health care payers and time horizon of
72 weeks were taken. The decision model was used to
quantify cost and effectiveness of alternative treatments.
One-way, two-way sensitivity analysis and treshold anal-
ysis were performed. RESULTS: Cost/patient cured and
cost/disease-free day were (in PLN, 1 USD  4,5 PLN)):
for T12 - 2199 and 10,6 for T16 - 2279 and 10,6, for I3 -
4207 and 16,9, for I4 - 4670 and 20,3. Incremental anal-
ysis suggests, that I3 and I4 are dominated programs,
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T12 and T16 are cost-effective. In deciding between
them, the size of the available budget must be brought to
bear. T12 ensures greatest effect within fixed budget.
One-way sensitivity analysis indicated, that T16 would
be optimal choice only when probability of complete cure
for T16 was 0,57 or probability of complete cure for
T12 was 0,41–0,43. In two-way sensitivity analysis T16
was optimal choice only when probablitity of complete
cure I3 and T12 or I4 and T12 were changed simulta-
neously. The treshold analysis suggests, that I3 and I4
would be optimal, when the price of itraconazole would
be decreased by 63%. CONCLUSION: In Poland T12
was the most cost-effective treatment of toenail onycho-
mycosis. 
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OBJECTIVE: To compare the economic impact of treat-
ing psoriatic patients in the Netherlands with calcipotriol
cream used daily combined with twice weekly UVB treat-
ment to emollient used daily combined with UVB given
three times weekly. METHODS: A pharmacoeconomic
analysis based on a Markov model was performed for the
Netherlands by combining information regarding 1) re-
duction in Psoriasis Assessment of Severity Index (PASI)
and relapse rates from a clinical study, 2) costs and stan-
dard clinical practice from a questionnaire survey and 3)
a Dutch dermatology consensus panel. Costs of UVB
treatments (staff, equipment, travelling), second line treat-
ment (PUVA), drug costs (calcipotriol, emollient) and in-
direct costs due to absence from work were included in
the analysis. RESULTS: The costs of treating psoriasis in
the Netherlands over 20 weeks with calcipotriol and twice
weekly UVB sessions is estimated to EUR 1,175.90. With
three weekly UVB sessions plus an emollient the costs is
estimated to EUR 1,212.14. CONCLUSION: Adding cal-
cipotriol to UVB phototherapy is a cost-neutral alterna-
tive to UVB phototherapy used with an emollient. But,
with calcipotriol and UVB as treatment strategy a num-
ber of essential beneficial effects for the patients are ob-
tained such as less exposure to potentially carcinogenic
radiation, less risk of developing photoaging of the skin and
less inconvenience to patients due to fewer UVB sessions.
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OBJECTIVE: The aim of this study was to compare the
cost-effectiveness of brinzolamide, a new topical carbonic
anhydrase inhibitor (CAI), with topical dorzolamide in
France, Italy and Portugal for the treatment of ocular hyper-
tension (OH) and primary open-angle glaucoma (POAG).
METHODS: High intra-ocular pressure (IOP) is the ma-
jor prognostic factor of POAG, and these two drugs were
developed to control it. Successful treatment was defined
as an IOP decrease of at least 5 mm Hg or any reduction
to a value below 21 mm Hg. Four double-masked well-
controlled randomized trials, three lasting 3-month and
one 12-months, compared the response rate of brinzola-
mide bid and tid versus dorzolamide tid, and the re-
sponse rate of brinzolamide bid versus bid dorzolamide
timolol combination bid. The local tolerance upon instil-
lation of the 2 drugs was compared through 2 dedicated
studies. The consequence of the instillation tolerance was
valued through an American HMO data base. The daily
cost of each drug took into account the number of drops
in a bottle, valued through a well-balanced analysis of
variance. In case of failure, either due to intolerance or
inadequate efficacy, the patients were treated with latan-
oprost. A model was developed to evaluate the cost of
initiating a treatment with a CAI (dorzolamide versus
brinzolamide) over 3 months. The economic perspective
taken was that of society. RESULTS: As a mono-therapy,
brinzolamide bid was found to be as efficacious as dor-
zolamide tid. Brinzolamide bid plus timolol was also as
efficacious as a combination of dorzolamide and timolol
bid. Stinging upon instillation with brinzolamide was far
less (P  0.0001) than with dorzolamide. The probability
that brinzolamide-treated patients would change therapy
was 1.28 (HMO study, P  0.05) less than the one of
dorzolamide-treated patients. The size of the brinzola-
mide drop is 18.7% smaller allowing 7 more therapy days
per bottle than dorzolamide mono-therapy when brin-
zolamide is used bid and 5 days when used tid. Conse-
quently, the breakeven price of brinzolamide was 10%
higher than dorzolamide in France and Portugal and 15%
in Italy, where CAIs were more often prescribed as mono-
therapy. CONCLUSION: Because (1) the daily cost of
brinzolamide is lower (2) brinzolamide can be prescribed
bid in mono-therapy (3) and brinzolamide stings less, our
model suggested that brinzolamide is a cost-effective al-
ternative in the treatment of OH and POAG.
